Company Overview and News
Etsy (ETSY) has seen its stock price soar following improved guidance from the company. The restructuring by the company under new management has paid dividends on the bottom line. This leaves valuations potentially stretched. However as I pointed out in an article in December, one can see this company as a serious challenger on the e-commerce space. Its international potential and secular trends means that the company does not have a low glass ceiling as some have posited.
We've heard a lot over the last few years about how we're increasingly turning into a "gig economy," where everyone is an Uber (UBER) driver, selling stuff on Etsy (NASDAQ:ETSY), or something like that. I argued in 2015 that this is not supported by the data, and now newly released Census data has basically proven me correct. Believing that the gig economy was taking over required looking at the data wrong, for example calling contractors "gigs," or not looking at the data at all.
What a run it has been for Etsy Inc (NASDAQ:ETSY). The online craft marketplace has been on a tear of late. Etsy stock now has tripled over the past year, with a 208% gain the 19th best among the nearly 1,900 stocks with a market capitalization over $2 billion.
MIK SQ SHOP AMZN SQNXF ETSY EBAY
Investors focused on the Computer and Technology space have likely heard of Etsy (ETSY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ETSY and the rest of the Computer and Technology group's stocks.
SPG.PRJ SPG ETSY
Online crafts marketplace Etsy Inc. ETSY 26.25% said it is increasing the transaction fees it charges, cheering Wall Street investors but angering some of the merchants that sell on the site.
Etsy Inc says that it will be introducing new subscription plans for sellers on its platform. These new plans will be Etsy Plus and Etsy Premium. The goal here is to give sellers more tools to work with and grow their business. Etsy Standard will be the free option and it includes all the current tools available to sellers.
Etsy Inc (NASDAQ:ETSY) stock soared more than 30% in early morning trading Thursday after the online marketplace lifted its 2018 revenue guidance and announced a new subscription service aimed at helping merchants improve their visibility on the site.
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney discusses the latest news from the Federal Reserve and European Central Bank, as well as today’s Initial Jobless Claims and Retail Sales reports. Later, he highlights Etsy (ETSY - Free Report) , a trending stock that soared in morning trading after raising its own revenue guidance.
Shares of Etsy (ETSY - Free Report) soared more than 30% in early morning trading Thursday after the online marketplace lifted its 2018 revenue guidance and announced a new subscription service aimed at helping merchants improve their visibility on the site.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Shares of Etsy, Inc. (NASDAQ: ETSY), an e-commerce website focused on handmade or vintage items, climbed Thursday after the company announced that it would be revising its seller transaction fee. In light of the changes to the fee structure, Etsy upped its guidance as well, and investors responded positively to the news, sending the shares up more than 28% in early trading.
20h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET